Memento Medicines launched with a $93 million Series A financing and secured licensing of a lead program for retinal diseases. The new ophthalmology-focused company is positioned to convert early-stage retinal science into a clinical development pathway using the funding to support program execution and research expansion. While the announcement emphasized the scale of the Series A and the retinal license acquisition, it did not detail the lead asset’s full mechanism or trial timing in the available text. The launch itself signals continued investment interest in ophthalmology as a dedicated therapeutic category rather than a portfolio add-on. Memento’s startup debut also reflects investor appetite for platform-agnostic assets in retinal disease, with funding intended to support both development activities and broader pipeline build-out.